NovoTTF-100A versus physician’s choice chemotherapy in recurrent glioblastoma: A randomised phase III trial of a novel treatment modality
Open accessAbstract
PURPOSE: NovoTTF-100A is a portable device delivering low-intensity, intermediate frequency electric fields via non-invasive, transducer arrays. Tumour Treatment Fields (TTF), a completely new therapeutic modality in cancer treatment, physically interfere with cell division. METHODS: Phase III trial of chemotherapy-free treatment of NovoTTF (20-24h/day) versus active chemotherapy in the treatment of patients with recurrent glioblastoma. Primary end-point was improvement of overall survival. RESULTS: Patients (median age 54 years (range 23-80), Karnofsky performance status 80% (range 50-100) were randomised to TTF alone (n=120) or active chemotherapy control (n=117). Number of prior treatments was two (range 1-6). Median survival was 6.6 versus 6.0 months (hazard ratio 0.86 [95% CI 0.66-1.12]; p=0.27), 1-year survival rate was 20% and 20%, progression-free survival rate at 6 months was 21.4% and 15.1% (p=0.13), respectively in TTF and active control patients. Responses were more common in the TTF arm (14% versus 9.6%, p=0.19). The TTF-related adverse events were mild (14%) to moderate (2%) skin rash beneath the transducer arrays. Severe adverse events occurred in 6% and 16% (p=0.022) of patients treated with TTF and chemotherapy, respectively. Quality of life analyses favoured TTF therapy in most domains. CONCLUSIONS: This is the first controlled trial evaluating an entirely novel cancer treatment modality delivering electric fields rather than chemotherapy. No improvement in overall survival was demonstrated, however efficacy and activity with this chemotherapy-free treatment device appears comparable to chemotherapy regimens that are commonly used for recurrent glioblastoma. Toxicity and quality of life clearly favoured TTF.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the EF-11 trial, a number of patients were discontinued from TTFields therapy very early (after less than 1 month) presumably due to absence of a treatment response rather than true tumor progression based on skepticism of the investigators.
“A number of patients were discontinued from TTFields therapy very early (after <1 month of therapy), presumably due to absence of a treatment response (rather than true tumor progression) based on skepticism of the investigators.”
From Tumor treating fields: A novel treatment modality and its use in brain tumors (2016) · cites this paper as [16]
The EF-11 trial showed objective responses with TTFields alone in 14% of patients compared with 9.6% in the control arm.
“Still it showed objective responses with TTFields alone in 14% of patients compared with 9.6% in the control arm.”
From Tumor treating fields: A novel treatment modality and its use in brain tumors (2016) · cites this paper as [16]
In the EF-11 trial, there were no differences in global health and social functioning between patients treated with TTFields and patients treated with chemotherapy.
“In the EF-11 trial, there were no differences in global health and social functioning between patients treated with TTFields or chemotherapy.”
From Tumor treating fields: A novel treatment modality and its use in brain tumors (2016) · cites this paper as [16]
In the EF-11 trial, cognitive and emotional functioning was higher in the TTFields group than in the chemotherapy group.
“In fact, cognitive and emotional functioning was higher in the TTFields group than in the chemotherapy group.16”
From Tumor treating fields: A novel treatment modality and its use in brain tumors (2016) · cites this paper as [16]
In recurrent glioblastoma, TTFields did not demonstrate improved outcome compared with best physicians' choice chemotherapy.
“In recurrent disease, the trial has not demonstrated improved outcome compared best physicians’ choice chemotherapy.”
From Tumor treating fields: A novel treatment modality and its use in brain tumors (2016) · cites this paper as [16]
Cites
Radiotherapy Plus Concomitant and Adjuvant Temozolomide for Glioblastoma
Stupp, R., Mason, W. P., van den Bent, M. J., Weller, M., Fisher, B., Taphoorn, M. J. B., Belanger, K., Brandes, A. A., Marosi, C., Bogdahn, U., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043330 · Cited by 21,807 · see citing works
Self-citationBevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma
Friedman, H. S., Prados, M. D., Wen, P. Y., Mikkelsen, T., Schiff, D., Abrey, L. E., Yung, W. K. A., Paleologos, N. A., Nicholas, M. K., Jensen, R. L., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.8721 · Cited by 2,463 · see citing works
Self-citationResponse criteria for phase II studies of supratentorial malignant glioma.
Macdonald, D. R., Cascino, T. L., Schold, S. C., & Cairncross, J. G. (1990) · Journal of Clinical Oncology · doi:10.1200/jco.1990.8.7.1277 · Cited by 2,409 · see citing works
Brem, H., Piantadosi, S., Burger, P. C., Walker, M., Selker, R. G., Vick, N. A., Black, K. L., Sisti, M. B., Brem, S. S., Mohr, G., et al. (1995) · The Lancet · doi:10.1016/s0140-6736(95)90755-6 · Cited by 1,390 · see citing works
Bevacizumab Plus Irinotecan in Recurrent Glioblastoma Multiforme
Vredenburgh, J. J., Desjardins, A., Herndon, J. E., Marcello, J. E., Reardon, D. A., Quinn, J. A., Rich, J. N., Sathornsumetee, S., Gururangan, S., Sampson, J. H., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.2440 · Cited by 1,383 · see citing works
Yung, W. K. A., Albright, R. E., Olson, J., Fredericks, R., Fink, K., Prados, M. D., Brada, M., Spence, A., Hohl, R. J., Shapiro, W., et al. (2000) · British Journal of Cancer · doi:10.1054/bjoc.2000.1316 · Cited by 929 · see citing works
Alternating electric fields arrest cell proliferation in animal tumor models and human brain tumors
Kirson, E. D., Dbalý, V., Tovaryš, F., Vymazal, J., Soustiel, J. F., Itzhaki, A., Mordechovich, D., Steinberg-Shapira, S., Gurvich, Z., Schneiderman, R., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0702916104 · Cited by 894 · see citing works
Self-citationDisruption of cancer cell replication by alternating electric fields
Kirson, E. D., Gurvich, Z., Schneiderman, R., Dekel, E., Itzhaki, A., Wasserman, Y., Schatzberger, R., & Palti, Y. (2004) · Cancer research · doi:10.1158/0008-5472.can-04-0083 · Cited by 827 · see citing works
Self-citationPhase II Trial of Gefitinib in Recurrent Glioblastoma
Rich, J. N., Reardon, D. A., Peery, T., Dowell, J. M., Quinn, J. A., Penne, K. L., Wikstrand, C. J., Van Duyn, L. B., Dancey, J. E., McLendon, R. E., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.08.110 · Cited by 734 · see citing works
FDA Drug Approval Summary: Bevacizumab (Avastin®) as Treatment of Recurrent Glioblastoma Multiforme
Cohen, M. H., Shen, Y. L., Keegan, P., & Pazdur, R. (2009) · The Oncologist · doi:10.1634/theoncologist.2009-0121 · Cited by 651 · see citing works
Wick, W., Puduvalli, V. K., Chamberlain, M. C., van den Bent, M. J., Carpentier, A. F., Cher, L., Mason, W. P., Weller, M., Hong, S., Musib, L. C., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.2595 · Cited by 518 · see citing works
Phase II Trial of Continuous Dose-Intense Temozolomide in Recurrent Malignant Glioma: RESCUE Study
Perry, J., Bélanger, K., Mason, W. P., Fulton, D. S., Kavan, P., Easaw, J. C., Shields, C., Kirby, S., Macdonald, D., Eisenstat, D. D., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.5520 · Cited by 379 · see citing works
Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse
Brada, M., Hoang-Xuan, K., Rampling, R., Dietrich, P.-Y., Dirix, L. Y., Macdonald, D., Heimans, J. J., Zonnenberg, B. A., Bravo-Marques, J. M., Henriksson, R., et al. (2001) · Annals of Oncology · doi:10.1023/a:1008382516636 · Cited by 372 · see citing works
Self-citationStratified phase II trial of cetuximab in patients with recurrent high-grade glioma
Neyns, B., Sadones, J., Joosens, E. J., Bouttens, F., Verbeke, L., Baurain, J., D'Hondt, L. A., Strauven, T., Chaskis, C., Veld, P. I. '., et al. (2009) · Annals of Oncology · doi:10.1093/annonc/mdp032 · Cited by 250 · see citing works
Kirson, E. D., Schneiderman, R. S., Dbalý, V., Tovaryš, F., Vymazal, J., Itzhaki, A., Mordechovich, D., Gurvich, Z., Shmueli, E., Goldsher, D., et al. (2009) · BMC Medical Physics · doi:10.1186/1756-6649-9-1 · Cited by 224 · see citing works
Self-citationConcerns about anti-angiogenic treatment in patients with glioblastoma multiforme
Verhoeff, J. J. C., van Tellingen, O., Claes, A., Stalpers, L. J. A., Linde, M. E. V., Richel, D. J., Leenders, W. P. J., & van Furth, W. R. (2009) · BMC Cancer · doi:10.1186/1471-2407-9-444 · Cited by 189 · see citing works
Robe, P. A. J. T., Martin, D., Nguyen-Khac, M., Artesi, M., Deprez, M., Albert, A., Vanbelle, S., Califice, S., Bredel, M., & Bours, V. (2009) · BMC Cancer · doi:10.1186/1471-2407-9-372 · Cited by 184 · see citing works
Bevacizumab and Recurrent Malignant Gliomas: A European Perspective
Wick, W., Weller, M., van den Bent, M. J., & Stupp, R. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.9027 · Cited by 126 · see citing works
Self-citationPhase II study of metronomic chemotherapy for recurrent malignant gliomas in adults
Kesari, S., Schiff, D., Doherty, L. M., Gigas, D. C., Batchelor, T. T., Muzikansky, A., O’Neill, A., Drappatz, J., Chen‐Plotkin, A. S., Ramakrishna, N. R., et al. (2007) · Neuro-Oncology · doi:10.1215/15228517-2007-006 · Cited by 120 · see citing works
Self-citationPhase II Study of Lonidamine and Diazepam in the Treatment of Recurrent Glioblastoma Multiforme
Oudard, S. M., Carpentier, A., Banu, E., Fauchon, F., Célérier, D., Poupon, M. F., Dutrillaux, B., Andrieu, J. M., & Delattre, J. ‐. (2003) · Journal of Neuro-Oncology · doi:10.1023/a:1023756707900 · Cited by 117 · see citing works
Repeated surgery for glioblastoma multiforme: only in combination with other salvage therapy
Mandl, E. S., Dirven, C. M. F., Buis, D. R., Postma, T. J., & Vandertop, W. P. (2008) · Surgical Neurology · doi:10.1016/j.surneu.2007.03.043 · Cited by 111 · see citing works
Temozolomide in the treatment of recurrent malignant glioma
Chang, S. M., Theodosopoulos, P., Lamborn, K., Malec, M., Rabbitt, J., Page, M., & Prados, M. D. (2004) · Cancer · doi:10.1002/cncr.11949 · Cited by 90 · see citing works
Puduvalli, V. K., Yung, W. K. A., Hess, K. R., Kuhn, J. G., Groves, M. D., Levin, V. A., Zwiebel, J. A., Chang, S. M., Cloughesy, T. F., Junck, L., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.09.096 · Cited by 88 · see citing works
Is reoperation for recurrence of glioblastoma justified?
Guyotat, J., Signorelli, F., Frappaz, D., Madarassy, G., Ricci, A. C., & Bret, P. (2000) · Oncology Reports · doi:10.3892/or.7.4.899 · Cited by 69 · see citing works
Salzberg, M., Kirson, E., Palti, Y., & Rochlitz, C. (2008) · Onkologie · doi:10.1159/000137713 · Cited by 68 · see citing works
Self-citationSchneiderman, R. S., Shmueli, E., Kirson, E. D., & Palti, Y. (2010) · BMC Cancer · doi:10.1186/1471-2407-10-229 · Cited by 65 · see citing works
Self-citationBalmaceda, C. M., Peereboom, D. M., Pannullo, S. C., Cheung, Y. K., Fisher, P. G., Alavi, J. Β., Sisti, M. B., Chen, J., & Fine, R. L. (2008) · Cancer · doi:10.1002/cncr.23167 · Cited by 61 · see citing works
Self-citationChamberlain, M. C., & Tsao-Wei, D. D. (2004) · Cancer · doi:10.1002/cncr.20072 · Cited by 59 · see citing works
Reoperation in Recurrent High-Grade Gliomas
Brandes, A. A., Vastola, F., & Monfardini, S. (1999) · American Journal of Clinical Oncology · doi:10.1097/00000421-199908000-00013 · Cited by 27 · see citing works
Rosenthal, M. A., Gruber, M. L., Glass, J., Nirenberg, A., Finlay, J. L., Höchster, H. S., & Muggia, F. M. (2000) · Journal of Neuro-Oncology · doi:10.1023/a:1006426215005 · Cited by 22 · see citing works
Mitosis interference of cancer cells during anaphase by electric field from NovoTTF-100A: An update.
Lee, S. X., Tun-Kyi, A., Wong, E. T., & Swanson, K. D. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.30.15_suppl.e21078 · Cited by 10 · see citing works
Self-citation(2010) · Neuro-Oncology · doi:10.1093/neuonc/noq116 · Cited by 3 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Stupp, R., Taillibert, S., Kanner, A., Read, W., Steinberg, D. M., Lhermitte, B., Toms, S., Idbaih, A., Ahluwalia, M. S., Fink, K., et al. (2017) · JAMA · doi:10.1001/jama.2017.18718 · Cited by 2,644 · see citing works
Self-citationGlioblastoma and Other Malignant Gliomas
Omuro, A. M. P. (2013) · JAMA · doi:10.1001/jama.2013.280319 · Cited by 2,308 · see citing works
EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood
Weller, M., van den Bent, M., Preusser, M., Le Rhun, E., Tonn, J. C., Minniti, G., Bendszus, M., Balana, C., Chinot, O., Dirven, L., et al. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-00447-z · Cited by 2,048 · see citing works
Self-citationManagement of glioblastoma: State of the art and future directions
Tan, A. C., Ashley, D. M., Lopez, G. Y., Malinzak, M. D., Friedman, H. S., & Khasraw, M. (2020) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21613 · Cited by 1,985 · see citing works
Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology
Gradishar, W. J., Anderson, B. O., Balassanian, R., Blair, S. L., Burstein, H. J., Cyr, A. E., ELIAS, A. D., Farrar, W. B., Forero, A., Giordano, S. H., et al. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.0012 · Cited by 1,607 · see citing works
Primary brain tumours in adults
Lapointe, S., Perry, A., & Butowski, N. A. (2018) · The Lancet · doi:10.1016/s0140-6736(18)30990-5 · Cited by 1,377 · see citing works
Current state of immunotherapy for glioblastoma
Lim, M. K., Xia, Y., Bettegowda, C., & Weller, M. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0003-5 · Cited by 1,373 · see citing works
Stupp, R., Taillibert, S., Kanner, A. A., Kesari, S., Steinberg, D. M., Toms, S. A., Taylor, L. P., Lieberman, F., Silvani, A., Fink, K. L., et al. (2015) · JAMA · doi:10.1001/jama.2015.16669 · Cited by 1,259 · see citing works
Self-citationGlioblastoma: Overview of Disease and Treatment
Davis, M. E. (2016) · Clinical journal of oncology nursing · doi:10.1188/16.cjon.s1.2-8 · Cited by 1,222 · see citing works
Wen, P. Y., Weller, M., Lee, E. Q., Alexander, B. M., Barnholtz-Sloan, J. S., Barthel, F. P., Batchelor, T. T., Bindra, R. S., Chang, S. M., Chiocca, E. A., et al. (2020) · Neuro-Oncology · doi:10.1093/neuonc/noaa106 · Cited by 1,168 · see citing works
Self-citationWeller, M., van den Bent, M. J., Tonn, J. C., Stupp, R., Preusser, M., Moyal, E. C., Henriksson, R., Rhun, É. L., Balañá, C., Chinot, O. L., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30194-8 · Cited by 1,094 · see citing works
Self-citationRecurrent Glioblastoma Treated with Recombinant Poliovirus
Desjardins, A., Gromeier, M., Herndon, J. E., Beaubier, N. T., Bolognesi, D. P., Friedman, A. H., Friedman, H. S., McSherry, F., Muscat, A. M., Nair, S. K., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1716435 · Cited by 821 · see citing works
High-grade glioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Stupp, R., Brada, M., van den Bent, M. J., Tonn, J.-C., & Pentheroudakis, G. E. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu050 · Cited by 773 · see citing works
Self-citationMolecular targeted therapy of glioblastoma
Rhun, É. L., Preusser, M., Roth, P., Reardon, D. A., van den Bent, M. J., Wen, P. Y., Reifenberger, G., & Weller, M. (2019) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2019.101896 · Cited by 688 · see citing works
Survival in glioblastoma: a review on the impact of treatment modalities
López, P. D. D., & Corrales-García, E. M. (2016) · Clinical & Translational Oncology · doi:10.1007/s12094-016-1497-x · Cited by 674 · see citing works
Central Nervous System Cancers, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology
Nabors, B., Portnow, J., Ahluwalia, M. S., Baehring, J. M., Brem, H., Brem, S. S., Butowski, N. A., Campian, J. L., Clark, S. W., Fabiano, A. J., et al. (2020) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2020.0052 · Cited by 543 · see citing works
Intratumoral oncolytic herpes virus G47∆ for residual or recurrent glioblastoma: a phase 2 trial
Todo, T., Ito, H., Ino, Y., Ohtsu, H., Ota, Y., Shibahara, J., & Tanaka, M. (2022) · Nature Medicine · doi:10.1038/s41591-022-01897-x · Cited by 533 · see citing works
Omuro, A., Vlahovic, G., Lim, M., Sahebjam, S., Baehring, J., Cloughesy, T., Voloschin, A., Ramkissoon, S. H., Ligon, K. L., Latek, R., et al. (2018) · Neuro-Oncology · doi:10.1093/neuonc/nox208 · Cited by 486 · see citing works
Wirsching, H., Galanis, E., & Weller, M. (2016) · Handbook of clinical neurology · doi:10.1016/b978-0-12-802997-8.00023-2 · Cited by 487 · see citing works
Primary brain tumours in adults
van den Bent, M. J., Geurts, M., French, P. J., Smits, M., Capper, D., Bromberg, J. E. C., & Chang, S. M. (2023) · The Lancet · doi:10.1016/s0140-6736(23)01054-1 · Cited by 436 · see citing works
Tumor Microenvironment and Differential Responses to Therapy
Hirata, E., & Sahai, E. (2017) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a026781 · Cited by 422 · see citing works
Tumor-Treating Fields: A Fourth Modality in Cancer Treatment
Mun, E. J., Babiker, H. M., Weinberg, U., Kirson, E. D., & Von Hoff, D. D. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-1117 · Cited by 380 · see citing works
Self-citationIdbaïh, A., Canney, M. S., Belin, L., Desseaux, C., Vignot, A., Bouchoux, G., Asquier, N., Law-Ye, B., Leclercq, D., Bissery, A., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-3643 · Cited by 367 · see citing works
Brown, C. E., Hibbard, J. C., Alizadeh, D., Blanchard, M. S., Natri, H. M., Wang, D., Ostberg, J. R., Aguilar, B., Wagner, J. R., Paul, J. A., et al. (2024) · Nature Medicine · doi:10.1038/s41591-024-02875-1 · Cited by 372 · see citing works
5-ALA and FDA Approval for Glioma Surgery
Hadjipanayis, C. G., & Stummer, W. (2019) · Journal of Neuro-Oncology · doi:10.1007/s11060-019-03098-y · Cited by 338 · see citing works
Potential Strategies Overcoming the Temozolomide Resistance for Glioblastoma
Jiapaer, S., Furuta, T., Tanaka, S., Kitabayashi, T., & Nakada, M. (2018) · Neurologia medico-chirurgica · doi:10.2176/nmc.ra.2018-0141 · Cited by 325 · see citing works
Giladi, M., Schneiderman, R. S., Voloshin, T., Porat, Y., Munster, M., Blat, R., Sherbo, S., Bomzon, Z., Urman, N., Itzhaki, A., et al. (2015) · Scientific Reports · doi:10.1038/srep18046 · Cited by 327 · see citing works
Self-citationTumour treating fields therapy for glioblastoma: current advances and future directions
Rominiyi, O., Vanderlinden, A., Clenton, S. J., Bridgewater, C. H., Al-Tamimi, Y., & Collis, S. J. (2020) · British Journal of Cancer · doi:10.1038/s41416-020-01136-5 · Cited by 319 · see citing works
Glioblastoma at the crossroads: current understanding and future therapeutic horizons
Singh, S., Dey, D., Barik, D., Mohapatra, I., Kim, S., Sharma, M., Prasad, S., Wang, P., Singh, A. R., & Singh, G. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02299-4 · Cited by 332 · see citing works
Oncolytic DNX-2401 virotherapy plus pembrolizumab in recurrent glioblastoma: a phase 1/2 trial
Nassiri, F., Patil, V. S., Yefet, L. S., Singh, O., Liu, J., Dang, R. M. A., Yamaguchi, T. N., Daras, M., Cloughesy, T. F., Colman, H., et al. (2023) · Nature Medicine · doi:10.1038/s41591-023-02347-y · Cited by 307 · see citing works
Self-citationNonsurgical Treatment of Recurrent Glioblastoma
Gallego, O. S. (2015) · Current Oncology · doi:10.3747/co.22.2436 · Cited by 296 · see citing works
Hombach‐Klonisch, S., Mehrpour, M., Shojaei, S., Harlos, C. H., Pitz, M. W., Hamaï, A., Siemianowicz, K., Likus, W., Wiecheć, E., Toyota, B. D., et al. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.10.017 · Cited by 290 · see citing works
Chiocca, E. A., Yu, J. S., Lukas, R. V., Solomon, I. H., Ligon, K. L., Nakashima, H., Triggs, D., Reardon, D. A., Wen, P. Y., Stopa, B. M., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aaw5680 · Cited by 264 · see citing works
Tumor Cell Infiltration into the Brain in Glioblastoma: From Mechanisms to Clinical Perspectives
Seker-Polat, F., Degirmenci, N. P., Solaroğlu, İ., & Onder, T. B. (2022) · Cancers · doi:10.3390/cancers14020443 · Cited by 261 · see citing works
Glioblastoma Therapy: Past, Present and Future
Obrador, E., Moreno-Murciano, P., Oriol‐Caballo, M., López‐Blanch, R., Pineda, B., Gutiérrez-Arroyo, J., Loras, A., Bonet, L. G. G., Martínez‐Cadenas, C., Estrela, J. M., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25052529 · Cited by 263 · see citing works
Central Nervous System Cancers
Nabors, B., Ammirati, M., Bierman, P. J., Brem, H., Butowski, N. A., Chamberlain, M. C., DeAngelis, L. M., Fenstermaker, R. A., Friedman, A. H., Gilbert, M. R., et al. (2013) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2013.0132 · Cited by 260 · see citing works
Self-citationTreatment of Glioblastoma (GBM) with the Addition of Tumor-Treating Fields (TTF): A Review
Fabian, D., Eibl, M. D. P. G. P., Alnahhas, I., Sebastian, N., Giglio, P., Puduvalli, V. K., Gonzalez, J., & Palmer, J. D. (2019) · Cancers · doi:10.3390/cancers11020174 · Cited by 241 · see citing works
Advances in Glioblastoma Therapy: An Update on Current Approaches
Angom, R. S., Nakka, N. M. R., & Bhattacharya, S. (2023) · Brain Sciences · doi:10.3390/brainsci13111536 · Cited by 235 · see citing works
Marenco-Hillembrand, L., Wijesekera, O., Suárez-Meade, P., Mampre, D. M., Jackson, C., Peterson, J., Trifiletti, D. M., Hammack, J. E., Ortiz, K. J., Lesser, E. R., et al. (2020) · Journal of Neuro-Oncology · doi:10.1007/s11060-020-03451-6 · Cited by 216 · see citing works
Drug delivery challenges and future of chemotherapeutic nanomedicine for glioblastoma treatment
Ganipineni, L. P., Danhier, F., & Véronique Préat, A. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.05.008 · Cited by 219 · see citing works
Tumor Treating Fields Perturb the Localization of Septins and Cause Aberrant Mitotic Exit
Gera, N., Yang, A., Holtzman, T. S., Lee, S. X., Wong, E. T., & Swanson, K. D. (2015) · PLOS ONE · doi:10.1371/journal.pone.0125269 · Cited by 217 · see citing works
Self-citationRecurrent Glioblastoma: From Molecular Landscape to New Treatment Perspectives
Birzu, C., French, P. J., Caccese, M., Cerretti, G., Idbaïh, A., Zagonel, V., & Lombardi, G. (2020) · Cancers · doi:10.3390/cancers13010047 · Cited by 218 · see citing works
Therapy for Diffuse Astrocytic and Oligodendroglial Tumors in Adults: ASCO-SNO Guideline
Mohile, N. A., Messersmith, H. J., Gatson, N. T., Hottinger, A. F., Lassman, A., Morton, J., Ney, D., Nghiemphu, P. L., Olar, A., Olson, J., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.21.02036 · Cited by 212 · see citing works
Self-citationPhotodynamic therapy (PDT) for malignant brain tumors – Where do we stand?
Quirk, B. J., Brandal, G., Donlon, S., Vera, J. C., Mang, T. S., Foy, A. B., Lew, S. M., Girotti, A. W., Jogal, S., LaViolette, P. S., et al. (2015) · Photodiagnosis and Photodynamic Therapy · doi:10.1016/j.pdpdt.2015.04.009 · Cited by 208 · see citing works
Chen, K., Chai, W., Lin, Y.-J., Lin, C.-J., Chen, P., Tsai, H., Huang, C.-Y., Kuo, J. S., Liu, H.-L., & Wei, K. (2021) · Science Advances · doi:10.1126/sciadv.abd0772 · Cited by 202 · see citing works
Therapeutic options in recurrent glioblastoma—An update
Seystahl, K., Wick, W., & Weller, M. (2016) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2016.01.018 · Cited by 199 · see citing works
Tumor treating fields: A new frontier in cancer therapy
Davies, A. M., Weinberg, U., & Palti, Y. (2013) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12112 · Cited by 193 · see citing works
Self-citationReardon, D. A., Desjardins, A., Vredenburgh, J. J., O’Rourke, D. M., Tran, D. D., Fink, K., Nabors, B., Li, G., Bota, D. A., Lukas, R. V., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1140 · Cited by 188 · see citing works
Fenstermaker, R. A., Ciesielski, M. J., Qiu, J., Yang, N., Frank, C. L., Lee, K. P., Mechtler, L. L., Belal, A., Ahluwalia, M. S., & Hutson, A. D. (2016) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-016-1890-x · Cited by 183 · see citing works
Toms, S. A., Kim, C., Nicholas, G. A., & Ram, Z. (2018) · Journal of Neuro-Oncology · doi:10.1007/s11060-018-03057-z · Cited by 183 · see citing works
Self-citationTumor treating fields: A novel treatment modality and its use in brain tumors
Hottinger, A. F., Pacheco, P., & Stupp, R. (2016) · Neuro-Oncology · doi:10.1093/neuonc/now182 · Cited by 177 · see citing works
Self-citationCentral Nervous System Cancers, Version 1.2015
Nabors, B., Portnow, J., Ammirati, M., Baehring, J. M., Brem, H., Brown, P. D., Butowski, N. A., Chamberlain, M. C., Fenstermaker, R. A., Friedman, A. H., et al. (2015) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2015.0148 · Cited by 177 · see citing works
Self-citationBinder, Z. A., Thorne, A. H., Bakas, S., Wileyto, E. P., Bilello, M., Akbari, H., Rathore, S., Ha, S. M., Zhang, L., Ferguson, C., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.06.006 · Cited by 166 · see citing works
Kast, R. E., Boockvar, J. A., Brüning, A., Cappello, F., Chang, W., Cvek, B., Dou, Q. P., Dueñas‐González, A., Efferth, T., Focosi, D., et al. (2013) · Oncotarget · doi:10.18632/oncotarget.969 · Cited by 167 · see citing works
Giladi, M., Munster, M., Schneiderman, R. S., Voloshin, T., Porat, Y., Blat, R., Zielinska-Chomej, K., Hååg, P., Bomzon, Z., Kirson, E. D., et al. (2017) · Radiation Oncology · doi:10.1186/s13014-017-0941-6 · Cited by 159 · see citing works
Self-citationRe-irradiation for recurrent glioblastoma (GBM): a systematic review and meta-analysis
Kazmi, F., Soon, Y. Y., Leong, Y. H., Koh, W. Y., & Vellayappan, B. A. (2018) · Journal of Neuro-Oncology · doi:10.1007/s11060-018-03064-0 · Cited by 158 · see citing works
on behalf of the GWCA1208 study group, Twelves, C. J., Sabel, M., Checketts, D., Miller, S., Tayo, B., Jové, M., Brazil, L., & Short, S. C. (2021) · British Journal of Cancer · doi:10.1038/s41416-021-01259-3 · Cited by 163 · see citing works
Virtual Human Models for Electromagnetic Studies and Their Applications
Makarov, S. N., Noetscher, G. M., Yanamadala, J., Piazza, M. W., Louie, S., Prokop, A., Nazarian, A., & Nummenmaa, A. R. (2017) · IEEE Reviews in Biomedical Engineering · doi:10.1109/rbme.2017.2722420 · Cited by 157 · see citing works
Recurrent Glioblastoma: A Review of the Treatment Options
Salgado, M. Á. V., Villamayor, M. L., Albarrán, V., Alía, V., Sotoca, P., Chamorro, J., Rosero, D. I., Barrill, A. M., Martín, M., Fernández, E., et al. (2023) · Cancers · doi:10.3390/cancers15174279 · Cited by 157 · see citing works
Mrugala, M. M., Engelhard, H. H., Dinh Tran, D., Kew, Y., Cavaliere, R., Villano, J. L., Annenelie Bota, D., Rudnick, J., Love Sumrall, A., Zhu, J.-J., et al. (2014) · Seminars in Oncology · doi:10.1053/j.seminoncol.2014.09.010 · Cited by 152 · see citing works
Self-citationWong, E. T., Lok, E., Gautam, S., & Swanson, K. D. (2015) · British Journal of Cancer · doi:10.1038/bjc.2015.238 · Cited by 152 · see citing works
Self-citationCentral nervous system gliomas
Reni, M., Mazza, E. A., Zanon, S. M., Gatta, G., & Vecht, C. J. (2017) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2017.03.021 · Cited by 151 · see citing works
Clinical activity and safety of atezolizumab in patients with recurrent glioblastoma
Lukas, R. V., Rodon, J. A., Becker, K. P., Wong, E. T., Shih, K. C., Touat, M., Fassò, M., Osborne, S., Molinero, L. L., O'Hear, C. E., et al. (2018) · Journal of Neuro-Oncology · doi:10.1007/s11060-018-2955-9 · Cited by 147 · see citing works
Self-citationTreatment options for progression or recurrence of glioblastoma: a network meta-analysis
McBain, C. A., Lawrie, T. A., Rogozińska, E., Kernohan, A., Robinson, T., & Jefferies, S. (2021) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd013579.pub2 · Cited by 150 · see citing works
Treatment of glioblastoma in adults
Wick, W., Osswald, M., Wick, A., & Winkler, F. (2018) · Therapeutic Advances in Neurological Disorders · doi:10.1177/1756286418790452 · Cited by 146 · see citing works
Nam, J. Y., & de Groot, J. (2017) · Journal of Oncology Practice · doi:10.1200/jop.2017.025536 · Cited by 143 · see citing works
Tumor treating fields increases membrane permeability in glioblastoma cells
Chang, E., Patel, C. B., Pohling, C., Young, C., Song, J., Flores, T. A., Zeng, Y., Joubert, L.-M., Arami, H., Natarajan, A., et al. (2018) · Cell Death Discovery · doi:10.1038/s41420-018-0130-x · Cited by 137 · see citing works
Radiation-induced cognitive toxicity: pathophysiology and interventions to reduce toxicity in adults
Wilke, C. T., Grosshans, D. R., Duman, J. G., Brown, P. D., & Li, J. (2017) · Neuro-Oncology · doi:10.1093/neuonc/nox195 · Cited by 134 · see citing works
Giladi, M., Weinberg, U., Schneiderman, R. S., Porat, Y., Munster, M., Voloshin, T., Blatt, R., Cahal, S., Itzhaki, A., Onn, A., et al. (2014) · Seminars in Oncology · doi:10.1053/j.seminoncol.2014.09.006 · Cited by 132 · see citing works
Self-citationPredicting the electric field distribution in the brain for the treatment of glioblastoma
Miranda, P. C., Mekonnen, A., Salvador, R., & Basser, P. J. (2014) · Physics in Medicine and Biology · doi:10.1088/0031-9155/59/15/4137 · Cited by 131 · see citing works
The tumour microenvironment, treatment resistance and recurrence in glioblastoma
White, J., White, M. P. J., Wickremesekera, A., Peng, L., & Gray, C. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-024-05301-9 · Cited by 142 · see citing works
Wenger, C., Miranda, P. C., Salvador, R., Thielscher, A., Bomzon, Z., Giladi, M., Mrugala, M. M., & Korshoej, A. R. (2018) · IEEE Reviews in Biomedical Engineering · doi:10.1109/rbme.2017.2765282 · Cited by 129 · see citing works
Key Clinical Principles in the Management of Glioblastoma
Kotecha, R. R., Odia, Y., Khosla, A. A., & Ahluwalia, M. S. (2023) · JCO Oncology Practice · doi:10.1200/op.22.00476 · Cited by 125 · see citing works
Management of glioblastoma after recurrence: A changing paradigm
Mallick, S., Benson, R., Hakim, A., & Rath, G. K. (2016) · Journal of the Egyptian National Cancer Institute · doi:10.1016/j.jnci.2016.07.001 · Cited by 124 · see citing works
Accelerator-based BNCT for patients with recurrent glioblastoma: a multicenter phase II study
Kawabata, S., Suzuki, M., Hirose, K., Tanaka, H., Katō, T., Goto, H., Narita, Y., & Miyatake, S. (2021) · Neuro-Oncology Advances · doi:10.1093/noajnl/vdab067 · Cited by 124 · see citing works
Wenger, C., Salvador, R., Basser, P. J., & Miranda, P. C. (2015) · Physics in Medicine and Biology · doi:10.1088/0031-9155/60/18/7339 · Cited by 121 · see citing works
Esquenazi, Y., Friedman, E. R., Liu, Z., Zhu, J., Hsu, S. H., & Tandon, N. (2017) · Neurosurgery · doi:10.1093/neuros/nyw174 · Cited by 119 · see citing works
Newly Diagnosed Glioblastoma: A Review on Clinical Management.
Lukas, R. V., Wainwright, D. A., Ladomersky, E., Sachdev, S., Sonabend, A. M., & Stupp, R. (2019) · PubMed · Cited by 117 · see citing works
Self-citationThe Mechanisms of Action of Tumor Treating Fields
Moser, J. C., Salvador, E., Deniz, K., Swanson, K. D., Tuszyński, J. A., Carlson, K. W., Karanam, N. K., Patel, C. B., Story, M. D., Lou, E., et al. (2022) · Cancer Research · doi:10.1158/0008-5472.can-22-0887 · Cited by 117 · see citing works
Leal, T. A. B., Kotecha, R. R., Ramlau, R., Zhang, L., Milanowski, J., Cobo, M., Roubec, J., Petruzelka, L. B., Havel, L., Kalmadi, S. R., et al. (2023) · The Lancet Oncology · doi:10.1016/s1470-2045(23)00344-3 · Cited by 112 · see citing works
Biological activity of tumor-treating fields in preclinical glioma models
Silginer, M., Weller, M., Stupp, R., & Roth, P. (2017) · Cell Death & Disease · doi:10.1038/cddis.2017.171 · Cited by 111 · see citing works
Self-citationEpidemiology, diagnosis, and optimal management of glioma in adolescents and young adults
Diwanji, T. P., Engelman, A., Snider, J. W., III, & Mohindra, P. (2017) · Adolescent Health Medicine and Therapeutics · doi:10.2147/ahmt.s53391 · Cited by 111 · see citing works
Lacouture, M. E., Davis, M. E., Elzinga, G., Butowski, N. A., Tran, D. D., Villano, J. L., DiMeglio, L., Davies, A. M., & Wong, E. T. (2014) · Seminars in Oncology · doi:10.1053/j.seminoncol.2014.03.011 · Cited by 111 · see citing works
Self-citationMehta, M. P., Wen, P. Y., Nishikawa, R., Reardon, D. A., & Peters, K. B. (2017) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2017.01.005 · Cited by 109 · see citing works
Kanner, A. A., Wong, E. T., Villano, J. L., & Ram, Z. (2014) · Seminars in Oncology · doi:10.1053/j.seminoncol.2014.09.008 · Cited by 109 · see citing works
Self-citationShteingauz, A., Porat, Y., Voloshin, T., Schneiderman, R. S., Munster, M., Zeevi, E., Kaynan, N., Gotlib, K., Giladi, M., Kirson, E. D., et al. (2018) · Cell Death & Disease · doi:10.1038/s41419-018-1085-9 · Cited by 107 · see citing works
Self-citationGlioblastoma: Background, Standard Treatment Paradigms, and Supportive Care Considerations
Ellor, S. V., Pagano-Young, T. A., & Avgeropoulos, N. G. (2014) · The Journal of Law Medicine & Ethics · doi:10.1111/jlme.12133 · Cited by 106 · see citing works
Tumor Treating Fields in the Management of Patients with Malignant Gliomas
Ghiaseddin, A. P., Shin, D. H., Melnick, K. F., & Tran, D. D. (2020) · Current Treatment Options in Oncology · doi:10.1007/s11864-020-00773-5 · Cited by 105 · see citing works
TGF-β Antibody Uptake in Recurrent High-Grade Glioma Imaged with 89Zr-Fresolimumab PET
den Hollander, M. W., Bensch, F., Glaudemans, A. W. J. M., Munnink, T. H. O., Enting, R. H., den Dunnen, W. F. A., Heesters, M. A. A. M., Kruyt, F. A. E., Hooge, M. N. L., de Groot, J. C., et al. (2015) · Journal of Nuclear Medicine · doi:10.2967/jnumed.115.154401 · Cited by 102 · see citing works
Drumm, M. R., Dixit, K., Grimm, S. A., Kumthekar, P., Lukas, R. V., Raizer, J. J., Stupp, R., Chheda, M. G., Kam, K.-L., McCord, M., et al. (2019) · Neuro-Oncology · doi:10.1093/neuonc/noz216 · Cited by 100 · see citing works
Self-citationPolymeric Nanoparticles for the Treatment of Malignant Gliomas
Mahmoud, B. S., Alamri, A. H., & McConville, C. (2020) · Cancers · doi:10.3390/cancers12010175 · Cited by 101 · see citing works
Giladi, M., Schneiderman, R. S., Porat, Y., Munster, M., Itzhaki, A., Mordechovich, D., Cahal, S., Kirson, E. D., Weinberg, U., & Palti, Y. (2014) · Pancreatology · doi:10.1016/j.pan.2013.11.009 · Cited by 98 · see citing works
Self-citationNayak, L., & Reardon, D. A. (2017) · CONTINUUM Lifelong Learning in Neurology · doi:10.1212/con.0000000000000554 · Cited by 96 · see citing works
PD-1/PD-L1 immune-checkpoint inhibitors in glioblastoma: A concise review
Caccese, M., Indraccolo, S., Zagonel, V., & Lombardi, G. (2019) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2018.12.002 · Cited by 96 · see citing works
An Overview of Sub-Cellular Mechanisms Involved in the Action of TTFields
Tuszynski, J., Wenger, C., Friesen, D., & Preto, J. (2016) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph13111128 · Cited by 95 · see citing works
Recent Advances in the Therapeutic Strategies of Glioblastoma Multiforme
Aldoghachi, A. F., Aldoghachi, A. F., Breyne, K., Ling, K., & Cheah, P.-S. (2022) · Neuroscience · doi:10.1016/j.neuroscience.2022.03.030 · Cited by 94 · see citing works
Mandel, J. J., Yust‐Katz, S., Patel, A. J., Cachia, D., Liu, D., Park, M., Yuan, Y., Kent, T. A., & de Groot, J. (2017) · Neuro-Oncology · doi:10.1093/neuonc/nox144 · Cited by 92 · see citing works
Rivera, F., Benavides, M., Gallego-Plazas, J., Guillén‐Ponce, C., Lopez-Martin, J. A., & Küng, M. (2018) · Pancreatology · doi:10.1016/j.pan.2018.10.004 · Cited by 89 · see citing works
Diagnosis and Management of Glioblastoma: A Comprehensive Perspective
Gilard, V., Tebani, A., Dabaj, I., Laquerrière, A., Fontanilles, M., Derrey, S., Marret, S., & Bekri, S. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11040258 · Cited by 86 · see citing works
Viral and other therapies for recurrent glioblastoma: is a 24-month durable response unusual?
Chiocca, E. A., Nassiri, F., Wang, J. Q., Peruzzi, P., & Zadeh, G. M. (2018) · Neuro-Oncology · doi:10.1093/neuonc/noy170 · Cited by 85 · see citing works
- Authors
- Stupp, R., Wong, E. T., Kanner, A. A., Steinberg, D., Engelhard, H., Heidecke, V., Kirson, E. D., Taillibert, S., Liebermann, F., Dbalý, V., Ram, Z., Villano, J. L., Rainov, N., Weinberg, U., Schiff, D., Kunschner, L., Raizer, J., Honnorat, J., Sloan, A., Malkin, M., Landolfi, J. C., Payer, F., Mehdorn, M., Weil, R. J., Pannullo, S. C., Westphal, M., Smrcka, M., Chin, L., Kostron, H., Hofer, S., Bruce, J., Cosgrove, R., Paleologous, N., Palti, Y., & Gutin, P. H.
- Affiliations
- Centre Hospitalier Universitaire Vaudois (CH)
- Harvard University (US)
- Tel Aviv Sourasky Medical Center (IL)
- Tel Aviv University (IL)
- University of Illinois Chicago (US)
- Pitié-Salpêtrière Hospital (FR)
- University of Pittsburgh (US)
- University of Virginia (US)
- Northwestern University (US)
- University Hospitals of Cleveland (US)
- Medical College of Wisconsin (US)
- John F. Kennedy Medical Center (US)
- University of Graz (AT)
- Cleveland Clinic (US)
- Cornell University (US)
- Universität Hamburg (DE)
- Boston University (US)
- Universität Innsbruck (AT)
- Columbia University (US)
- Tufts University (US)
- Endeavor Health (US)
- Memorial Sloan Kettering Cancer Center (US)
- ORCID
- Venue
- European Journal of Cancer
- Publisher
- Elsevier BV
- Published
- 2012-09
- Volume
- 48
- Issue
- 14
- Pages
- 2192-2202
- ISSN
- 0959-8049 (ISSN-L)
- OpenAlex
- W2149768128
- Cited by
- 862
- References
- 32
- Citations by year
- 2026: 39 · 2025: 56 · 2024: 82 · 2023: 75 · 2022: 89 · 2021: 77 · 2020: 63 · 2019: 69 · 2018: 75 · 2017: 58 · 2016: 65 · 2015: 56 · 2014: 30 · 2013: 21 · 2012: 6
- FWCI
- 17.23
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- European Journal of Cancer (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- IRIS (submittedVersion)
- SERVAL (Université de Lausanne) (submittedVersion)
- Funders
- National Cancer Institute
- Topics
- Health Sciences › Medicine › Genetics › Glioma Diagnosis and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biophysics › Electromagnetic Fields and Biological Effects
- Physical Sciences › Mathematics › Modeling and Simulation › Mathematical Biology Tumor Growth
- Keywords
- electric field treatment, recurrent glioblastoma, chemotherapy-free treatment, overall survival, progression-free survival, treatment-related adverse events, quality of life, transducer array
- MeSH terms
- Adult, Aged, Aged, 80 and over, Antineoplastic Agents, Brain Neoplasms, Electric Stimulation Therapy, Europe, Female, Glioblastoma, Humans, Israel, Magnetic Resonance Imaging, Male, Middle Aged, Neoplasm Recurrence, Local, Quality of Life, Risk Factors, Time Factors, United States, Proportional Hazards Models, Treatment Outcome, Karnofsky Performance Status, Risk Assessment, Disease-Free Survival, Kaplan-Meier Estimate, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
